Find out what’s going on with your RAPS. Programs, conference information and celebrations of members’ accomplishments are detailed here.
The Regulatory Affairs Professionals Society (RAPS) has, since its founding 1976, been the preeminent group representing regulatory affairs professionals involved in the regulation of healthcare products. With support from a dedicated professional staff, RAPS is led by 13 highly committed, distinguished and accomplished members of its board of directors.
Regulatory Focus reflects on the 2012 RAPS awards honorees and the awards they received.
FDA recently released its final rule on current Good Manufacturing Practices for combination products. The rule is likely to clarify some questions and raise others. A workshop hosted by RAPS and the Combination Products Coalition will examine the rule and FDA’s plan for implementation.
Pharmacovigilance has been defined by the World Health Organization as, “The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.” Pharmacovigilance (or risk management) should help to inform both healthcare professionals and patients, allowing them to make educated decisions when choosing a treatment.
Regulatory Focus is for regulatory professionals written by regulatory professionals.
The publication takes a look at the important topics facing regulatory professionals in a changing global healthcare landscape. From topics ranging from research and development to labeling and marketing, the articles try to analyze, inform, and educate readers about the issues at the forefront of the industry.
Rated as the number one benefit by the members of RAPS, Regulatory Focus strives to provide the best and most current information to regulatory professionals so they can succeed and advance at every stage in their careers.
For questions or comments on our content or to find out more about Regulatory Focus, please visit our About RF page.